Recursion Pharmaceuticals's total assets for Q4 2024 were $1.45B, an increase of 99.39% from the previous quarter. RXRX total liabilities were $413.82M for the fiscal quarter, a 104.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.